Nr566 Week 8 Final Exam Due 1St March 2026 Complete
Actual Exam Questions 1- 100 Nr566 Advanced
Pharmacology For Care Of The Family Nr 566 Midterm
And Finals Examplify Online Proctored Exam Actual
Questions And Correct Answers (Verified Answers)
,CORE DOMAINS
Pharmacokinetics and Pharmacodynamics
Pharmacogenomics and Personalized Medicine
Cardiovascular Pharmacology
Respiratory Pharmacology
Endocrine Pharmacology
Gastrointestinal and Renal Pharmacology
Neurological and Psychopharmacology
Anti-infective Pharmacology
Special Populations and Family Care
INTRODUCTION
The NR566 Week 8 Final Examination assesses the advanced practice nursing
student's mastery of pharmacologic principles essential for family nurse
practitioner practice. It evaluates understanding of pharmacokinetics,
pharmacodynamics, pharmacogenomics, and clinical application across diverse
patient populations. The examination employs multiple-choice and scenario-based
questions to test foundational theory, applied professional knowledge, and critical
decision-making. Emphasis is placed on drug interactions, age-related changes,
therapeutic monitoring, and evidence-based prescribing. This assessment prepares
candidates for autonomous pharmacologic management in primary care and family
practice settings.
SECTION ONE: QUESTIONS 1–100
1. A 72-year-old male with hepatic cirrhosis is prescribed a highly protein-
bound medication (warfarin, 99% bound). The provider should anticipate
that the patient will experience which effect compared to a patient without
cirrhosis?
A. Decreased free drug levels requiring dose increase
B. Increased free drug levels requiring dose reduction
,C. No change in dosing because protein binding does not affect free drug
D. Increased metabolism requiring more frequent dosing
B. Increased free drug levels requiring dose reduction
RATIONALE: In cirrhosis, albumin synthesis decreases, leading to fewer
protein-binding sites and more free (active) warfarin. The NR 566 curriculum
emphasizes that reduced protein binding increases drug toxicity risk, so doses must
be reduced and INR monitored more frequently. Option A reverses the relationship;
option C ignores the central role of free drug concentration; option D confuses
metabolism with protein binding.
2. A patient receives an oral medication that undergoes extensive first-pass
metabolism. The bioavailability is approximately 30%. Which statement best
explains the clinical implication of this pharmacokinetic property?
A. The oral dose must be lower than the IV dose to achieve the same effect
B. The oral dose must be higher than the IV dose to achieve the same systemic
effect
C. The drug should only be given by the sublingual route to bypass metabolism
D. First-pass metabolism increases the oral drug's therapeutic index
B. The oral dose must be higher than the IV dose to achieve the same systemic
effect
RATIONALE: Extensive first-pass metabolism reduces the fraction of drug
reaching systemic circulation, requiring higher oral doses to achieve therapeutic
plasma concentrations. Option A is incorrect because IV administration bypasses
first-pass metabolism entirely. Option C is not always practical or appropriate.
Option D is incorrect because first-pass metabolism does not increase therapeutic
index.
3. A drug with a half-life of 12 hours is initiated. Approximately how many
half-lives are required to reach steady-state, and what is the corresponding
time frame?
, A. 3-4 half-lives; 36-48 hours
B. 5 half-lives; 60 hours
C. 1 half-life; 12 hours
D. 10 half-lives; 120 hours
B. 5 half-lives; 60 hours
RATIONALE: Steady-state is reached in approximately 4-5 half-lives (94-97%
of steady-state). For a drug with a 12-hour half-life, steady-state is achieved in 60
hours (5 half-lives). At this point, drug elimination equals drug administration. This
principle is essential for therapeutic drug monitoring of drugs such as digoxin and
lithium.
4. A 6-month-old infant receives a water-soluble medication. Compared to an
adult, the infant is expected to have:
A. Higher peak plasma concentration due to larger volume of distribution for
water-soluble drugs
B. Lower volume of distribution requiring higher mg/kg dosing
C. Same volume of distribution as adult
D. Increased plasma protein binding reducing free drug
A. Higher peak plasma concentration due to larger volume of distribution for
water-soluble drugs
RATIONALE: Infants have higher total body water (70-80% vs. 60% in
adults) and lower plasma protein binding (lower albumin and alpha-1-acid
glycoprotein), resulting in a larger volume of distribution for water-soluble drugs.
This requires higher weight-based dosing (mg/kg) to achieve therapeutic plasma
concentrations. Plasma protein binding is reduced, increasing free drug fraction.
5. A patient with a history of diabetes and hypertension is prescribed
lisinopril. What is a potential adverse effect that should be discussed with the
patient?
Actual Exam Questions 1- 100 Nr566 Advanced
Pharmacology For Care Of The Family Nr 566 Midterm
And Finals Examplify Online Proctored Exam Actual
Questions And Correct Answers (Verified Answers)
,CORE DOMAINS
Pharmacokinetics and Pharmacodynamics
Pharmacogenomics and Personalized Medicine
Cardiovascular Pharmacology
Respiratory Pharmacology
Endocrine Pharmacology
Gastrointestinal and Renal Pharmacology
Neurological and Psychopharmacology
Anti-infective Pharmacology
Special Populations and Family Care
INTRODUCTION
The NR566 Week 8 Final Examination assesses the advanced practice nursing
student's mastery of pharmacologic principles essential for family nurse
practitioner practice. It evaluates understanding of pharmacokinetics,
pharmacodynamics, pharmacogenomics, and clinical application across diverse
patient populations. The examination employs multiple-choice and scenario-based
questions to test foundational theory, applied professional knowledge, and critical
decision-making. Emphasis is placed on drug interactions, age-related changes,
therapeutic monitoring, and evidence-based prescribing. This assessment prepares
candidates for autonomous pharmacologic management in primary care and family
practice settings.
SECTION ONE: QUESTIONS 1–100
1. A 72-year-old male with hepatic cirrhosis is prescribed a highly protein-
bound medication (warfarin, 99% bound). The provider should anticipate
that the patient will experience which effect compared to a patient without
cirrhosis?
A. Decreased free drug levels requiring dose increase
B. Increased free drug levels requiring dose reduction
,C. No change in dosing because protein binding does not affect free drug
D. Increased metabolism requiring more frequent dosing
B. Increased free drug levels requiring dose reduction
RATIONALE: In cirrhosis, albumin synthesis decreases, leading to fewer
protein-binding sites and more free (active) warfarin. The NR 566 curriculum
emphasizes that reduced protein binding increases drug toxicity risk, so doses must
be reduced and INR monitored more frequently. Option A reverses the relationship;
option C ignores the central role of free drug concentration; option D confuses
metabolism with protein binding.
2. A patient receives an oral medication that undergoes extensive first-pass
metabolism. The bioavailability is approximately 30%. Which statement best
explains the clinical implication of this pharmacokinetic property?
A. The oral dose must be lower than the IV dose to achieve the same effect
B. The oral dose must be higher than the IV dose to achieve the same systemic
effect
C. The drug should only be given by the sublingual route to bypass metabolism
D. First-pass metabolism increases the oral drug's therapeutic index
B. The oral dose must be higher than the IV dose to achieve the same systemic
effect
RATIONALE: Extensive first-pass metabolism reduces the fraction of drug
reaching systemic circulation, requiring higher oral doses to achieve therapeutic
plasma concentrations. Option A is incorrect because IV administration bypasses
first-pass metabolism entirely. Option C is not always practical or appropriate.
Option D is incorrect because first-pass metabolism does not increase therapeutic
index.
3. A drug with a half-life of 12 hours is initiated. Approximately how many
half-lives are required to reach steady-state, and what is the corresponding
time frame?
, A. 3-4 half-lives; 36-48 hours
B. 5 half-lives; 60 hours
C. 1 half-life; 12 hours
D. 10 half-lives; 120 hours
B. 5 half-lives; 60 hours
RATIONALE: Steady-state is reached in approximately 4-5 half-lives (94-97%
of steady-state). For a drug with a 12-hour half-life, steady-state is achieved in 60
hours (5 half-lives). At this point, drug elimination equals drug administration. This
principle is essential for therapeutic drug monitoring of drugs such as digoxin and
lithium.
4. A 6-month-old infant receives a water-soluble medication. Compared to an
adult, the infant is expected to have:
A. Higher peak plasma concentration due to larger volume of distribution for
water-soluble drugs
B. Lower volume of distribution requiring higher mg/kg dosing
C. Same volume of distribution as adult
D. Increased plasma protein binding reducing free drug
A. Higher peak plasma concentration due to larger volume of distribution for
water-soluble drugs
RATIONALE: Infants have higher total body water (70-80% vs. 60% in
adults) and lower plasma protein binding (lower albumin and alpha-1-acid
glycoprotein), resulting in a larger volume of distribution for water-soluble drugs.
This requires higher weight-based dosing (mg/kg) to achieve therapeutic plasma
concentrations. Plasma protein binding is reduced, increasing free drug fraction.
5. A patient with a history of diabetes and hypertension is prescribed
lisinopril. What is a potential adverse effect that should be discussed with the
patient?
